Genetic Risk of Ankylosing Spondylitis and Second-Line Therapy Need in Crohn’s Disease: A Mendelian Randomization Study
Mahmud Omar, Mohammad Omar, Yonatan Shneor Patt, Offir Ukashi, Yousra Sharif, Adi Lahat, Christian Phillip Selinger, Kassem Sharif, Antonio M Caballero-Mateos · 2024
Read Genetic Risk of Ankylosing Spondylitis and Second-Line Therapy Need in Crohn’s Disease: A Mendelian Randomization Study by Mahmud Omar, Mohammad Omar, Yonatan Shneor Patt, Offir Ukashi, Yousra Sharif, Adi Lahat, Christian Phillip Selinger, Kassem Sharif, Antonio M Caballero-Mateos (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11678710.txt.
Description
Doctors use gene data to test whether a spine disease raises the need for stronger drugs in bowel disease. The two diseases, Crohn disease and ankylosing spondylitis, share swollen tissue paths and often strike the same people. If genes for the spine disease also push the bowel disease to a harsher course, care could plan for that early. The team used a gene method that mimics a trial, with gene marks as stand-ins for the spine disease.
Two large gene sets fed the test, one per disease. The main method found that spine-linked genes more than doubled the odds of needing second-line bowel drugs. A second method gave an even higher mark, and the link held after a strong outlier gene was cut. Checks for bias backed the read. The team urges joint care plans for patients with both.
Catalog record
| CREATOR | Mahmud Omar, Mohammad Omar, Yonatan Shneor Patt, Offir Ukashi, Yousra Sharif, Adi Lahat, Christian Phillip Selinger, Kassem Sharif, Antonio M Caballero-Mateos |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |